OncoMatch/Clinical Trials/NCT06218914
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
Is NCT06218914 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including NT-112: Autologous, engineered T Cells targeting KRAS G12D and AZD0240: Autologous, engineered T Cells targeting KRAS G12D for non-small cell lung cancer.
Treatment: NT-112: Autologous, engineered T Cells targeting KRAS G12D · AZD0240: Autologous, engineered T Cells targeting KRAS G12D — Phase I Study, a master protocol to investigate TCR-Engineered T cells recognizing KRAS mutations in adult subjects with Unresectable, Advanced, and/or Metastatic Solid Tumors.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Small Cell Lung Carcinoma
Colorectal Cancer
Pancreatic Cancer
Endometrial Cancer
Tumor Agnostic
Biomarker criteria
Required: KRAS G12D
Tumors must harbor a KRAS G12D variant mutation
Disease stage
Required: Stage III, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic standard of care treatment regimen
after at least 1 line of approved systemic standard of care (SOC) treatment regimen
Cannot have received: adoptive cell and gene therapy
History of prior adoptive cell and gene therapy
Cannot have received: allogeneic stem cell transplant
allogeneic stem cell transplant
Cannot have received: solid organ transplantation
solid organ transplantation
Cannot have received: pan-KRAS or KRAS G12D targeting agents
Exception: unless presence of KRAS G12D mutation is confirmed after the completion of treatment with pan-KRAS or KRAS G12D targeting agents
Prior treatment with pan-KRAS or KRAS G12D targeting agents unless presence of KRAS G12D mutation is confirmed after the completion of treatment with pan-KRAS or KRAS G12D targeting agents
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Research Site · Duarte, California
- Research Site · Los Angeles, California
- Research Site · Newport Beach, California
- Research Site · Jacksonville, Florida
- Research Site · Chicago, Illinois
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06218914 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior adoptive cell and gene therapy, allogeneic stem cell transplant, solid organ transplantation disqualifies patients from enrollment.
Does this trial require KRAS?
Yes, KRAS G12D is a required biomarker for enrollment.
What disease stage is eligible?
Stage III or IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify